BMO Capital analyst Jeffrey Silber maintained a Buy rating on Adtalem Global Education today and set a price target of $158.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jeffrey Silber has given his Buy rating due to a combination of factors that highlight Adtalem Global Education’s strong performance and potential for growth. The company has exceeded expectations with accelerated enrollment growth and margin expansion, despite ongoing investments in growth. Although there were some challenges with Chamberlain’s post-licensure programs, these are expected to be addressed over time, and other segments like Walden and the Medical and Veterinary programs have shown robust growth.
Adtalem’s financial results for the first quarter of fiscal year 2026 were impressive, with adjusted earnings per share surpassing both consensus and internal estimates. The company’s revenue and enrollment growth figures also outperformed expectations, particularly in the Walden and Medical and Veterinary segments. Despite some execution issues, management remains optimistic about improvements in the latter half of the year. The maintained guidance for FY2026, along with a focus on the promising Medical and Healthcare sectors, supports the positive outlook and Buy rating.
In another report released today, Barrington also reiterated a Buy rating on the stock with a $170.00 price target.